Market Research Logo

The Global Radiopharmaceutical Market Forecast 2017-2027

The Global Radiopharmaceutical Market Forecast 2017-2027

Radiopharmaceuticals – our new study reveals trends, R&D progress, and predicted revenues

Where is the Radiopharmaceutical market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 234-page report provides 193 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biosimulation market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, there are forecasts for 6 Applications, 11 Radioisotopes, 2 Sources, and 4 end-users

Radiopharmaceuticals, by Application
  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Neurology
  • Nephrology
  • Others
  • Radiopharmaceuticals, by Radioisotope
  • Tec 99
  • Fluorine 18
  • Iodine131
  • Lutetium 177
  • Yttrium 90
  • Gallium 68
  • Gallium 67
  • Rubidium 82
  • Iodine 123
  • Iodine 125
  • Indium 111
  • Others
  • Radiopharmaceuticals, by Source
  • Cyclotrons
  • Nuclear Reactors
  • Radiopharmaceuticals, by End User
  • Hospitals
  • Diagnostic Imaging Centres
  • Ambulatory Surgical Centres
  • Cancer Research Institutes
  • In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 21 leading national markets:
    • North America:
    • The US
    • Canada
    • Latin America:
    • Brazil
    • Mexico
    • Rest of Latin America
    • Western Europe:
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • Nordic Countries
    • Benelux
    • Rest of Western Europe
    • Eastern Europe:
    • Russia
    • Poland
    • Rest of Eastern Europe
    • APAC:
    • Japan
    • China
    • India
    • Australia & New Zealand
    • ASEAN countries
    • Rest of Asia-Pacific
    • MEA:
    • South Africa
    • GCC
    • North African countries
    • Rest of MEA
    The report also includes profiles and historical results for some of the leading companies in the radiopharmaceutical market, with a focus on the radiopharmaceutical segment of these companies’ operations.

    Leading companies and the potential for market growth

    Overall world revenue for radiopharmaceutical will surpass $5bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing cost of drug development and increasing need for simulation software to reduce

    Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

    How the Biosimulation Market report helps you

    In summary, our 234-page report provides you with the following knowledge:
    • Revenue forecasts to 2027 for the Biosimulation market and 4 different segmentations, with forecasts for 6 Applications, 11 Radioisotopes, 2 Sources and 4 End Users – discover the industry’s prospects, finding the most lucrative places for investments and revenues
    • Revenue forecasts to 2027 for 21 of the leading national markets – US, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Poland, Russia, Japan, China, India, Australia & New Zealand, ASEAN, GCC, South Africa, Northern African Countries
    • Discussion of what stimulates and restrains companies and the market
    • Prospects for established firms and those seeking to enter the market – including company profiles and forecasts for 9 companies’ biosimulation segment revenues to 2027
    Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

    Information found nowhere else

    With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

    Visiongain’s study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

    Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

    The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


    1. Report Overview
    1.1 Introduction
    1.2 Why You Should Read This Report
    1.3 Key Questions Answered by This Analytical Report
    1.4 Who is This Report For?
    1.5 Methodology
    1.6 Frequently Asked Questions (FAQ)
    1.7 Associated Visiongain Reports
    1.8 About Visiongain
    2. Radiopharmaceutical Market Overview
    2.1 Introduction
    2.1.1 Market Definition
    2.1.2 Market Taxonomy
    2.2 Global Radiopharmaceutical Market Size and Forecast
    2.3 Market Dynamics
    2.3.1 Global Radiopharmaceutical Market: Drivers
    2.3.1.1 Evolution towards Centralized Pharmacies
    2.3.1.2 Increasing Number of PET and SPECT Scanners Globally
    2.3.1.3 Minimizing the Dose in Paediatric Nuclear Imaging
    2.3.1.4 Consolidation of Supply Chain
    2.3.1.5 Growing Interest of Investors of Conventional Pharmaceutical Industries in the Therapeutic Area
    2.3.1.6 Russian Supply Initiative for Mo-99
    2.3.1.7 Increasing Domestic Radiopharmaceutical Production
    2.3.1.8 Rising Incidence of Cancer and Cardiovascular Diseases
    2.3.1.9 Diagnostics Remain a Key Focus of Radiopharmaceuticals Companies
    2.3.1.10 Advancement in Radiotracers
    2.3.2 Global Radiopharmaceutical Market: Restraints
    2.3.2.1 Price Sensitivity and Lack of Specified Guidelines
    2.3.2.2 Shorter Half Life of Radiopharmaceuticals Devices
    2.3.2.3 Closing of Ageing Research Reactors Worldwide
    2.3.3 Global Radiopharmaceutical Market: Opportunity
    2.3.3.1 Alternative Diagnostic Radiopharmaceuticals Solutions
    2.3.3.2 Lutetium 177
    2.3.4 Global Radiopharmaceutical Market: Trends
    2.3.4.1 Increasing focus of Manufacturers towards Diagnostic Tracers
    2.3.4.2 Increasing Penetration of Radio-therapeutics
    2.3.4.3 Fluoro-deoxy glucose (FDG)
    2.3.4.4 Gallium-68
    2.3.4.5 Nuclear pharmacies
    2.3.4.6 Shortage of molybdenum-99/technetium-99m
    2.4 Key Regulations
    3. Global Radiopharmaceutical Market Analysis and Forecast, By Application
    3.1 Introduction
    3.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Application
    3.2 Global Radiopharmaceutical Market Size and Forecast, By Application
    3.2.1 Oncology Segment
    3.2.2 Cardiology Segment
    3.2.3 Gastroenterology
    3.2.4 Neuroendocrinology
    3.2.5 Neurology
    3.2.6 Nephrology
    3.2.7 Others
    3.3 Global Radiopharmaceutical Market Attractiveness Index, By Application
    4. Global Radiopharmaceutical Market Analysis and Forecast, By Radioisotope
    4.1 Introduction
    4.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Radioisotope
    4.2 Global Radiopharmaceutical Market Size and Forecast, By Radioisotope
    4.2.1 Tec. 99 Segment
    4.2.2 F18 Segment
    4.2.3 Iodine 131 Segment
    4.2.4 Lutetium 177 Segment
    4.2.5 Yttrium 90 Segment
    4.2.6 Gallium 68 Segment
    4.2.7 Gallium 67 Segment
    4.2.8 Rubidium 82 Segment
    4.2.9 Iodine 123 Segment
    4.2.10 Iodine 125 Segment
    4.2.11 Indium 111 Segment
    4.2.12 Others Segment
    4.3 Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    5. Global Radiopharmaceutical Market Analysis and Forecast, By Source
    5.1 Introduction
    5.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Source
    5.2 Global Radiopharmaceutical Market Size and Forecast, By Source
    5.2.1 Cyclotrons Segment
    5.2.2 Nuclear Reactors Segment
    5.3 Global Radiopharmaceutical Market Attractiveness Index, By Source
    6. Global Radiopharmaceutical Market Analysis and Forecast, By End User
    6.1 Introduction
    6.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By End User
    6.2 Global Radiopharmaceutical Market Size and Forecast, By End User
    6.2.1 Hospitals Segment
    6.2.2 Diagnostic Imaging Centres Segment
    6.2.3 Ambulatory Surgical Centres Segment
    6.2.4 Cancer Research Institute Segment
    6.3 Global Radiopharmaceutical Market Attractiveness Index, By End User
    7. Global Radiopharmaceutical Market Analysis and Forecast, By Region
    7.1 Introduction
    7.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Region
    7.2 Global Radiopharmaceutical Market Size and Forecast, By Region
    7.2.1 North America
    7.2.2 Latin America
    7.2.3 Western Europe
    7.2.4 Eastern Europe
    7.2.5 Asia Pacific
    7.2.6 MEA
    7.3 Global Radiopharmaceutical Market Attractiveness Index, By Region
    8. North America Radiopharmaceutical Market Analysis and Forecast, 2016–2027
    8.1 Introduction
    8.1.1 North America Radiopharmaceutical Market
    8.1.2 North America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
    8.2 North America Radiopharmaceutical Market Size and Forecast, By Country
    8.2.1 The U.S. Radiopharmaceutical Market
    8.2.2 Canada Radiopharmaceutical Market
    8.3 North America Radiopharmaceutical Market Size and Forecast, By Application
    8.4 North America Radiopharmaceutical Market Size and Forecast, By Radioisotope
    8.5 North America Radiopharmaceutical Market Size and Forecast, By Source
    8.6 North America Radiopharmaceutical Market Size and Forecast, By End User
    8.7 North America Radiopharmaceutical Market Attractiveness Index
    8.7.1 North America Radiopharmaceutical Market Attractiveness Index, By Country
    8.7.2 North America Radiopharmaceutical Market Attractiveness Index, By Application
    8.7.3 North America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    8.7.4 North America Radiopharmaceutical Market Attractiveness Index, By Source
    8.7.5 North America Radiopharmaceutical Market Attractiveness Index, By End User
    9. Latin America Radiopharmaceutical Market Analysis and Forecast, 2016–2027
    9.1 Introduction
    9.1.1 Latin America Radiopharmaceutical Market
    9.1.2 Latin America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
    9.2 Latin America Radiopharmaceutical Market Size and Forecast, By Country
    9.2.1 Brazil Radiopharmaceutical Market
    9.2.2 Mexico Radiopharmaceutical Market
    9.2.3 Rest of Latin America Radiopharmaceutical Market
    9.3 Latin America Radiopharmaceutical Market Size and Forecast, By Application
    9.4 Latin America Radiopharmaceutical Market Size and Forecast, By Radioisotope
    9.5 Latin America Radiopharmaceutical Market Size and Forecast, By Source
    9.6 Latin America Radiopharmaceutical Market Size and Forecast, By End User
    9.7 Latin America Radiopharmaceutical Market Attractiveness Index
    9.7.1 Latin America Radiopharmaceutical Market Attractiveness Index, By Country
    9.7.2 Latin America Radiopharmaceutical Market Attractiveness Index, By Application
    9.7.3 Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    9.7.4 Latin America Radiopharmaceutical Market Attractiveness Index, By Source
    9.7.5 Latin America Radiopharmaceutical Market Attractiveness Index, By End User
    10. Western Europe Radiopharmaceutical Market Analysis and Forecast, 2017–2027
    10.1 Introduction
    10.1.1 Western Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
    10.2 Western Europe Radiopharmaceutical Market Size and Forecast, By Country
    10.2.1 U.K. Radiopharmaceutical Market
    10.2.2 France Radiopharmaceutical Market
    10.2.3 Germany Radiopharmaceutical Market
    10.2.4 Italy Radiopharmaceutical Market
    10.2.5 Spain Radiopharmaceutical Market
    10.2.6 Nordic Radiopharmaceutical Market
    10.2.7 Benelux Radiopharmaceutical Market
    10.2.8 Rest of Western Europe Radiopharmaceutical Market
    10.3 Western Europe Radiopharmaceutical Market Size and Forecast, By Application
    10.4 Western Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
    10.5 Western Europe Radiopharmaceutical Market Size and Forecast, By Source
    10.6 Western Europe Radiopharmaceutical Market Size and Forecast, By End User
    10.7 Western Europe Radiopharmaceutical Market Attractiveness Index
    10.7.1 Western Europe Radiopharmaceutical Market Attractiveness Index, By Country
    10.7.2 Western Europe Radiopharmaceutical Market Attractiveness Index, By Application
    10.7.3 Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    10.7.4 Western Europe Radiopharmaceutical Market Attractiveness Index, By Source
    10.7.5 Western Europe Radiopharmaceutical Market Attractiveness Index, By End User
    11. Eastern Europe Radiopharmaceutical Market Analysis and Forecast, 2017–2027
    11.1 Introduction
    11.1.1 Eastern Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
    11.2 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Country
    11.2.1 Russia Radiopharmaceutical Market
    11.2.2 Poland Radiopharmaceutical Market
    11.2.3 Rest of Eastern Europe Radiopharmaceutical Market
    11.3 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Application
    11.4 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
    11.5 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Source
    11.6 Eastern Europe Radiopharmaceutical Market Size and Forecast, By End User
    11.7 Eastern Europe Radiopharmaceutical Market Attractiveness Index
    11.7.1 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country
    11.7.2 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application
    11.7.3 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    11.7.4 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source
    11.7.5 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User
    12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast, 2017–2027
    12.1 Introduction
    12.1.1 Asia Pacific Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
    12.1.2 Asia Pacific Radiopharmaceutical Market, BPS Analysis, By Country
    12.2 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Country
    12.2.1 China Radiopharmaceutical Market
    12.2.2 India Radiopharmaceutical Market
    12.2.3 Australia and New Zealand Radiopharmaceutical Market
    12.2.4 ASEAN Radiopharmaceutical Market
    12.2.5 Japan Radiopharmaceutical Market
    12.2.6 Rest of Asia Pacific Radiopharmaceutical Market
    12.3 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Application
    12.4 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Radioisotope
    12.5 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Source
    12.6 Asia Pacific Radiopharmaceutical Market Size and Forecast, By End User
    12.7 Asia Pacific Radiopharmaceutical Market Attractiveness Index
    12.7.1 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country
    12.7.2 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application
    12.7.3 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    12.7.4 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source
    12.7.5 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User
    13. MEA Radiopharmaceutical Market Analysis and Forecast, 2017–2027
    13.1 Introduction
    13.1.1 MEA Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
    13.2 MEA Radiopharmaceutical Market Size and Forecast, By Country
    13.2.1 GCC Countries Radiopharmaceutical Market
    13.2.2 South Africa Radiopharmaceutical Market
    13.2.3 North Africa Radiopharmaceutical Market
    13.2.4 Rest of MEA Radiopharmaceutical Market
    13.3 MEA Radiopharmaceutical Market Size and Forecast, By Application
    13.4 MEA Radiopharmaceutical Market Size and Forecast, By Radioisotope
    13.5 MEA Radiopharmaceutical Market Size and Forecast, By Source
    13.6 MEA Radiopharmaceutical Market Size and Forecast, By End User
    13.7 MEA Radiopharmaceutical Market Attractiveness Index
    13.7.1 MEA Radiopharmaceutical Market Attractiveness Index, By Country
    13.7.2 MEA Radiopharmaceutical Market Attractiveness Index, By Application
    13.7.3 MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    13.7.4 MEA Radiopharmaceutical Market Attractiveness Index, By Source
    13.7.5 MEA Radiopharmaceutical Market Attractiveness Index, By End User
    14. Leading Companies in the Radiopharmaceutical Market
    14.1 Competition Dashboard
    14.2 Company Share Analysis
    14.3 Company Profiles
    14.3.1 Siemens AG
    14.3.1.1 Basic Information
    14.3.1.2 Company Overview
    14.3.1.3 Product Offering
    14.3.1.4 Financial Statements
    14.3.1.5 Company Strategy
    14.3.1.6 Key Developments
    14.3.2 Eckert & Ziegler
    14.3.2.1 Basic Information
    14.3.2.2 Company Overview
    14.3.2.3 Product Offering
    14.3.2.4 Financial Statements
    14.3.2.5 Key Developments
    14.3.2.6 Company Strategy
    14.3.3 Lantheus Medical Imaging, Inc.
    14.3.3.1 Basic Information
    14.3.3.2 Company Overview
    14.3.3.3 Product Offering
    14.3.3.4 Financial Statements
    14.3.3.5 Key Developments
    14.3.3.6 Company Strategy
    14.3.4 Cardinal Health, Inc.
    14.3.4.1 Basic Information
    14.3.4.2 Company Overview
    14.3.4.3 Product Offering
    14.3.4.4 Financial Statements
    14.3.4.5 Key Developments
    14.3.4.6 Company Strategy
    14.3.5 Bayer AG
    14.3.5.1 Basic Information
    14.3.5.2 Company Overview
    14.3.5.3 Product Offering
    14.3.5.4 Financial Statements
    14.3.5.5 Key Developments
    14.3.5.6 Company Strategy
    14.3.6 Bracco Imaging S.P.A
    14.3.6.1 Basic Information
    14.3.6.2 Company Overview
    14.3.6.3 Product Offering
    14.3.6.4 Key Developments
    14.3.6.5 Company Strategy
    14.3.7 Nordion Inc.
    14.3.7.1 Basic Information
    14.3.7.2 Company Overview
    14.3.7.3 Product Offering
    14.3.7.4 Key Developments
    14.3.7.5 Company Strategy
    14.3.8 Advanced Accelerator Applications S.A.
    14.3.8.1 Basic Information
    14.3.8.2 Company Overview
    14.3.8.3 Product Offering
    14.3.8.4 Financial Statements
    14.3.8.5 Key Developments
    14.3.8.6 Company Strategy
    14.3.9 Mallinckrodt PLC
    14.3.9.1 Basic Information
    14.3.9.2 Company Overview
    14.3.9.3 Product Offering
    14.3.9.4 Financial Statements
    14.3.9.5 Key Developments
    14.4 Other Companies of Interest in the Radiopharmaceutical Market
    15. Conclusion
    16. Glossary
    Visiongain Report Sales Order Form
    Associated Visiongain Reports
    Appendix A
    About Visiongain
    Appendix B
    Visiongain report evaluation form
    List of Figures
    Figure 2.1 Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2015–2027
    Figure 3.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015–2027
    Figure 3.2: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015–2027
    Figure 3.4: Global Oncology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 3.5: Global Cardiology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 3.6: Global Gastroenterology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Segment, 2014–2027
    Figure 3.7: Global Neuroendocrinology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 3.8: Global Neurology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 3.9: Global Nephrology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 3.10: Global Other Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 3.11: Global Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
    Figure 4.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Radioisotope Segment, 2015–2027
    Figure 4.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Tec. 99 Segment, 2014–2027
    Figure 4.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By F18 Segment, 2014–2027
    Figure 4.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 131 Segment, 2014–2027
    Figure 4.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Lutetium 177 Segment, 2014–2027
    Figure 4.6: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Yttrium 90 Segment, 2014–2027
    Figure 4.7: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 68 Segment, 2014–2027
    Figure 4.8: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 67 Segment, 2014–2027
    Figure 4.9: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rubidium 82 Segment, 2014–2027
    Figure 4.10: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 123 Segment, 2014–2027
    Figure 4.11: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 125 Segment, 2014–2027
    Figure 4.12: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Indium 111 Segment, 2014–2027
    Figure 4.13: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Others Segment, 2014–2027
    Figure 4.14: Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
    Figure 5.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Source Segment, 2015–2027
    Figure 5.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cyclotrons Segment, 2014–2027
    Figure 5.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Nuclear Reactors Segment, 2014–2027
    Figure 5.4: Global Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
    Figure 6.1: Global Radiopharmaceutical Market AGR (%) Comparison, By End User Segment, 2015–2027
    Figure 6.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Hospitals Segment, 2014–2027
    Figure 6.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Diagnostic Imaging Centres Segment, 2014–2027
    Figure 6.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Ambulatory Surgical Centres Segment, 2014–2027
    Figure 6.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cancer Research Institute Segment, 2014–2027
    Figure 6.6: Global Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
    Figure 7.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Region, 2015–2027
    Figure 7.2: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 7.3: Latin American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 7.4: Western European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 7.5: Eastern European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 7.6: Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 7.7: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 7.8: Global Radiopharmaceutical Market Attractiveness Index, By Region, 2017–2027
    Figure 8.1: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 8.2: North American Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
    Figure 8.3: US Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 8.4: Canadian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 8.5: North American Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
    Figure 8.6: North American Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
    Figure 8.7: North American Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
    Figure 8.8: North American Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
    Figure 8.9: North American Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
    Figure 9.1: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 9.2: Latin America Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
    Figure 9.3: Brazilian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 9.4: Mexican Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 9.5: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rest of Latin America, 2014–2027
    Figure 9.6: Latin America Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
    Figure 9.7: Latin America Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
    Figure 9.8: Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
    Figure 9.9: Latin America Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
    Figure 9.10: Latin America Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
    Figure 10.1: Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.2: Western Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
    Figure 10.3: UK Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.4: French Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.5: German Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.6: Italian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.7: Spanish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.8: Nordic Radiopharmaceutical Market Value (US$m) Forecast and AGR (%),2014–2027
    Figure 10.9: Benelux Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.10: Rest of Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 10.11: Western Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
    Figure 10.12: Western Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
    Figure 10.13: Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
    Figure 10.14: Western Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
    Figure 10.15: Western Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
    Figure 11.1: Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 11.2: Eastern Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
    Figure 11.3: Russian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 11.4: Polish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 11.5: Rest of Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 11.6: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
    Figure 11.7: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
    Figure 11.8: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
    Figure 11.9: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
    Figure 11.10: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
    Figure 12.1 Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 12.2: Asia Pacific Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
    Figure 12.3: Chinese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 12.4: Indian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 12.5: Australia and New Zealand Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 12.6: ASEAN Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 12.7: Japanese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 12.8: Rest of Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
    Figure 12.9: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
    Figure 12.10: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
    Figure 12.11: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
    Figure 12.12: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
    Figure 12.13: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report